首页 > 最新文献

European Cardiology Review最新文献

英文 中文
Grading of Aortic Stenosis: Is it More Complicated in Women? 主动脉狭窄的分级:女性是否更复杂?
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.13
Dana Cramariuc, Edda Bahlmann, Eva Gerdts

Aortic stenosis (AS) is the most common valvular heart disease and the main indication for valvular replacement in older women. Correct AS grading is mandatory for an adequate selection of patients for both surgical and transcatheter aortic valve replacement. Women and men have different AS severity grades at the same level of aortic valve calcification. Moreover, besides having smaller cardiac volumes, left ventricular outflow tract and aortic size, women have a specific pattern of left ventricular structural and functional remodelling in response to the AS-related chronic pressure overload. Here, the sex-specific cardiac changes in AS that make AS grading more challenging in women, with consequences for the management and outcome of this group of patients, are reviewed.

主动脉瓣狭窄(Aortic stenosis, AS)是最常见的瓣膜性心脏病,也是老年女性瓣膜置换术的主要适应症。正确的AS分级是必要的,以充分选择手术和经导管主动脉瓣置换术的患者。在主动脉瓣钙化程度相同的情况下,女性和男性的AS严重程度不同。此外,除了心脏容量、左心室流出道和主动脉瓣大小较小外,女性在应对as相关的慢性压力过载时,还具有特定的左心室结构和功能重构模式。本文回顾了AS患者的性别特异性心脏变化,这些变化使女性的AS分级更具挑战性,并对这组患者的治疗和预后产生了影响。
{"title":"Grading of Aortic Stenosis: Is it More Complicated in Women?","authors":"Dana Cramariuc,&nbsp;Edda Bahlmann,&nbsp;Eva Gerdts","doi":"10.15420/ecr.2022.13","DOIUrl":"https://doi.org/10.15420/ecr.2022.13","url":null,"abstract":"<p><p>Aortic stenosis (AS) is the most common valvular heart disease and the main indication for valvular replacement in older women. Correct AS grading is mandatory for an adequate selection of patients for both surgical and transcatheter aortic valve replacement. Women and men have different AS severity grades at the same level of aortic valve calcification. Moreover, besides having smaller cardiac volumes, left ventricular outflow tract and aortic size, women have a specific pattern of left ventricular structural and functional remodelling in response to the AS-related chronic pressure overload. Here, the sex-specific cardiac changes in AS that make AS grading more challenging in women, with consequences for the management and outcome of this group of patients, are reviewed.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/84/ecr-17-e21.PMC9820123.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
SECURE, ADVOR and REVIVED: Clinical Trials Presented at ESC 2022. 安全,ADVOR和复苏:ESC 2022年的临床试验
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.43
Guiomar Mendieta

In this article, three important clinical trials presented at the 2022 European Society of Cardiology Congress have been selected for a brief discussion. These are the SECURE, ADVOR and REVIVED-BCIS2 trials, all of which are investigator-initiated studies whose findings are of interest given their potential to impact clinical practice, ultimately improving current patient care and clinical outcomes.

本文选取2022年欧洲心脏病学会大会上提出的三个重要临床试验进行简要讨论。这些是SECURE、ADVOR和REVIVED-BCIS2试验,它们都是研究者发起的研究,其研究结果具有影响临床实践的潜力,最终改善当前患者的护理和临床结果。
{"title":"SECURE, ADVOR and REVIVED: Clinical Trials Presented at ESC 2022.","authors":"Guiomar Mendieta","doi":"10.15420/ecr.2022.43","DOIUrl":"https://doi.org/10.15420/ecr.2022.43","url":null,"abstract":"<p><p>In this article, three important clinical trials presented at the 2022 European Society of Cardiology Congress have been selected for a brief discussion. These are the SECURE, ADVOR and REVIVED-BCIS2 trials, all of which are investigator-initiated studies whose findings are of interest given their potential to impact clinical practice, ultimately improving current patient care and clinical outcomes.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/99/ecr-17-e28.PMC9947931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Slow Coronary Blood Flow: Pathogenesis and Clinical Implications 冠状动脉血流缓慢:发病机制和临床意义
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.46
A. Aparicio, J. Cuevas, C. Morís, María Martín
Coronary slow flow (CSF) phenomenon, also known as cardiac syndrome Y, is defined as the delayed opacification of the coronary vasculature at the distal level. Different hypotheses and theories have been postulated about its substrate and mechanism, such as microvascular and endothelial dysfunction. Several studies have confirmed that CSF is a cause of ischaemia detected by non-invasive testing. Clinically, it can present as angina pectoris, acute coronary syndrome and sudden cardiac death. It has an incidence of 1–5% in patients undergoing coronary angiography and has been most frequently found in young men who are smokers with metabolic syndrome. There are no established treatments for CSF and further studies are still necessary.
冠状动脉慢流(CSF)现象,又称心脏Y综合征,定义为冠状动脉远端血管的迟发性混浊。关于其底物和机制,人们提出了不同的假设和理论,如微血管和内皮功能障碍。几项研究证实,脑脊液是通过无创检测检测到的缺血的一个原因。临床上可表现为心绞痛、急性冠状动脉综合征、心源性猝死。在接受冠状动脉造影的患者中发病率为1-5%,最常见于有代谢综合征的年轻男性吸烟者。脑脊液的治疗方法尚无定论,仍需进一步研究。
{"title":"Slow Coronary Blood Flow: Pathogenesis and Clinical Implications","authors":"A. Aparicio, J. Cuevas, C. Morís, María Martín","doi":"10.15420/ecr.2021.46","DOIUrl":"https://doi.org/10.15420/ecr.2021.46","url":null,"abstract":"Coronary slow flow (CSF) phenomenon, also known as cardiac syndrome Y, is defined as the delayed opacification of the coronary vasculature at the distal level. Different hypotheses and theories have been postulated about its substrate and mechanism, such as microvascular and endothelial dysfunction. Several studies have confirmed that CSF is a cause of ischaemia detected by non-invasive testing. Clinically, it can present as angina pectoris, acute coronary syndrome and sudden cardiac death. It has an incidence of 1–5% in patients undergoing coronary angiography and has been most frequently found in young men who are smokers with metabolic syndrome. There are no established treatments for CSF and further studies are still necessary.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74191539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Circulating Biomarkers in Lower Extremity Artery Disease 下肢动脉疾病的循环生物标志物
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.58
L. Ziegler, U. Hedin, A. Gottsäter
Lower extremity artery disease (LEAD), a chronic condition with disturbed lower extremity circulation due to narrowing of the arteries, is predominantly caused by atherosclerosis and is associated with the presence of cardiovascular risk factors and an increased risk of cardiovascular events. LEAD is prevalent among older individuals and predicted to rise with the ageing population. In progressive disease, the patient experiences symptoms of ischaemia when walking and, in advanced critical limb-threatening ischaemia, even at rest. However, LEAD is asymptomatic in most patients, delaying diagnosis and treatment. In this setting, circulating biomarkers may facilitate earlier diagnosis in selected individuals. This review provides a broad overview of the circulating biomarkers investigated to date in relation to LEAD and discusses their usefulness in clinical practice.
下肢动脉疾病(LEAD)是一种慢性疾病,由于动脉狭窄导致下肢循环紊乱,主要由动脉粥样硬化引起,与心血管危险因素的存在和心血管事件的风险增加有关。铅在老年人中普遍存在,预计将随着人口老龄化而上升。在进行性疾病中,患者在行走时出现缺血症状,在晚期危及肢体的严重缺血中,甚至在休息时也出现缺血症状。然而,大多数患者的铅是无症状的,延误了诊断和治疗。在这种情况下,循环生物标志物可能有助于选定个体的早期诊断。这篇综述提供了迄今为止与铅相关的循环生物标志物的广泛概述,并讨论了它们在临床实践中的实用性。
{"title":"Circulating Biomarkers in Lower Extremity Artery Disease","authors":"L. Ziegler, U. Hedin, A. Gottsäter","doi":"10.15420/ecr.2021.58","DOIUrl":"https://doi.org/10.15420/ecr.2021.58","url":null,"abstract":"Lower extremity artery disease (LEAD), a chronic condition with disturbed lower extremity circulation due to narrowing of the arteries, is predominantly caused by atherosclerosis and is associated with the presence of cardiovascular risk factors and an increased risk of cardiovascular events. LEAD is prevalent among older individuals and predicted to rise with the ageing population. In progressive disease, the patient experiences symptoms of ischaemia when walking and, in advanced critical limb-threatening ischaemia, even at rest. However, LEAD is asymptomatic in most patients, delaying diagnosis and treatment. In this setting, circulating biomarkers may facilitate earlier diagnosis in selected individuals. This review provides a broad overview of the circulating biomarkers investigated to date in relation to LEAD and discusses their usefulness in clinical practice.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79903091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin 高敏感性肌钙蛋白时代的2型心肌梗死与心肌损伤
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2021.42
R. Rafiudeen, P. Barlis, H. White, W. van Gaal
Troponin has been the cornerstone of the definition of MI since its introduction to clinical practice. High-sensitivity troponin has allowed clinicians to detect degrees of myocardial damage at orders of magnitude smaller than previously and is challenging the definitions of MI, with implications for patient management and prognosis. Detection and diagnosis are no doubt enhanced by the greater sensitivity afforded by these markers, but perhaps at the expense of specificity and clarity. This review focuses on the definitions, pathophysiology, prognosis, prevention and management of type 2 MI and myocardial injury. The five types of MI were first defined in 2007 and were recently updated in 2018 in the fourth universal definition of MI. The authors explore how this pathophysiological classification is used in clinical practice, and discuss some of the unanswered questions in this era of availability of high-sensitivity troponin.
肌钙蛋白自引入临床实践以来一直是心肌梗死定义的基石。高灵敏度肌钙蛋白使临床医生能够检测到比以前更小数量级的心肌损伤程度,并对心肌梗死的定义提出了挑战,对患者管理和预后具有重要意义。这些标记物所提供的更高的灵敏度无疑提高了检测和诊断,但也许是以牺牲特异性和清晰度为代价的。本文就2型心肌梗死和心肌损伤的定义、病理生理、预后、预防和治疗作一综述。这五种类型的心肌梗死于2007年首次定义,最近在2018年更新了心肌梗死的第四种通用定义。作者探讨了这种病理生理分类如何在临床实践中使用,并讨论了在这个高敏感性肌钙蛋白可用的时代一些未解决的问题。
{"title":"Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin","authors":"R. Rafiudeen, P. Barlis, H. White, W. van Gaal","doi":"10.15420/ecr.2021.42","DOIUrl":"https://doi.org/10.15420/ecr.2021.42","url":null,"abstract":"Troponin has been the cornerstone of the definition of MI since its introduction to clinical practice. High-sensitivity troponin has allowed clinicians to detect degrees of myocardial damage at orders of magnitude smaller than previously and is challenging the definitions of MI, with implications for patient management and prognosis. Detection and diagnosis are no doubt enhanced by the greater sensitivity afforded by these markers, but perhaps at the expense of specificity and clarity. This review focuses on the definitions, pathophysiology, prognosis, prevention and management of type 2 MI and myocardial injury. The five types of MI were first defined in 2007 and were recently updated in 2018 in the fourth universal definition of MI. The authors explore how this pathophysiological classification is used in clinical practice, and discuss some of the unanswered questions in this era of availability of high-sensitivity troponin.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78734074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
European Society of Cardiology Highlights: Late-breaking Trials – COVID-19 欧洲心脏病学会重点:最新的试验- COVID-19
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.03
Maki Komiyama, K. Hasegawa
Colchicine: ECLA PHRI COLCOVID Trial The anti-inflammatory effect of colchicine on the cytokine storm made it a promising candidate for the treatment of COVID-19, and the drug is known to be safe and well tolerated. Randomised controlled trials (RCTs) in hospitalised patients have reported limited clinical benefits of colchicine, such as increased time to clinical deterioration (mean [SD] event-free survival time was 18.6 [0.83] days in the control group versus 20.7 [0.31] in the colchicine group; log-rank p=0.03) and reduced duration of oxygen supplementation therapy and hospitalisation.3,4
秋水仙碱对细胞因子风暴的抗炎作用使其成为治疗COVID-19的有希望的候选药物,并且已知该药物安全且耐受性良好。在住院患者中进行的随机对照试验(RCTs)报告了秋水仙碱有限的临床益处,例如延长了临床恶化的时间(对照组的平均无事件生存时间为18.6[0.83]天,而秋水仙碱组为20.7[0.31]天;Log-rank p=0.03),并缩短了补氧治疗和住院时间
{"title":"European Society of Cardiology Highlights: Late-breaking Trials – COVID-19","authors":"Maki Komiyama, K. Hasegawa","doi":"10.15420/ecr.2022.03","DOIUrl":"https://doi.org/10.15420/ecr.2022.03","url":null,"abstract":"Colchicine: ECLA PHRI COLCOVID Trial The anti-inflammatory effect of colchicine on the cytokine storm made it a promising candidate for the treatment of COVID-19, and the drug is known to be safe and well tolerated. Randomised controlled trials (RCTs) in hospitalised patients have reported limited clinical benefits of colchicine, such as increased time to clinical deterioration (mean [SD] event-free survival time was 18.6 [0.83] days in the control group versus 20.7 [0.31] in the colchicine group; log-rank p=0.03) and reduced duration of oxygen supplementation therapy and hospitalisation.3,4","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82640472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation. 利用免疫球蛋白游离轻链,新型炎症生物标志物治疗房颤。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.30
Akira Matsumori

AF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activation releases proinflammatory cytokines that activate nuclear factor (NF)-κB, which regulates the production of immunoglobulin free light chains (FLCs). Serum FLC levels are increased in patients with AF, and FLCs are biomarkers of inflammation. Inflammasomes and NF-κB may be targets for anti-inflammatory strategies to prevent and treat AF when FLC levels are elevated. This review discusses the role of inflammation in the pathogenesis of AF, as well as FLCs as novel inflammatory biomarkers for the management of AF.

房颤是最常见的心律失常。越来越多的证据表明炎症机制在其发病机制中起重要作用;炎症小体的激活有助于房颤的发生和进展。nod样受体-pyrin结构域-3 (NLRP3)炎症小体激活的增加释放促炎细胞因子,激活核因子(NF)-κB,从而调节免疫球蛋白游离轻链(FLCs)的产生。房颤患者血清FLC水平升高,FLC是炎症的生物标志物。当FLC水平升高时,炎性小体和NF-κB可能是预防和治疗房颤的抗炎策略的目标。这篇综述讨论了炎症在房颤发病机制中的作用,以及FLCs作为房颤治疗的新型炎症生物标志物。
{"title":"Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation.","authors":"Akira Matsumori","doi":"10.15420/ecr.2022.30","DOIUrl":"https://doi.org/10.15420/ecr.2022.30","url":null,"abstract":"<p><p>AF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activation releases proinflammatory cytokines that activate nuclear factor (NF)-κB, which regulates the production of immunoglobulin free light chains (FLCs). Serum FLC levels are increased in patients with AF, and FLCs are biomarkers of inflammation. Inflammasomes and NF-κB may be targets for anti-inflammatory strategies to prevent and treat AF when FLC levels are elevated. This review discusses the role of inflammation in the pathogenesis of AF, as well as FLCs as novel inflammatory biomarkers for the management of AF.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/74/ecr-17-e22.PMC9820057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Scoring Systems to Predict Survival or Neurological Recovery after Out-of-hospital Cardiac Arrest. 预测院外心脏骤停后生存或神经恢复的评分系统。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.05
Rishi Naik, Indrajeet Mandal, Diana A Gorog

Numerous prediction scores have been developed to better inform clinical decision-making following out-of-hospital cardiac arrest (OHCA), however, there is no consensus among clinicians over which score to use. The aim of this review was to identify and compare scoring systems to predict survival and neurological recovery in patients with OHCA. A structured literature search of the MEDLINE database was carried out from inception to December 2021. Studies developing or validating scoring systems to predict outcome following OHCA were selected. Relevant data were extracted and synthesised for narrative review. In total, 16 scoring systems were identified: one predicting the probability of return of spontaneous circulation, six predicting survival to hospital discharge and nine predicting neurological outcome. NULL-PLEASE and CAST are recommended as the best scores to predict mortality and neurological outcome, respectively, due to the extent of external validation, ease of use and high predictive value of the variables. Whether use of these scores can lead to more cost-effective service delivery remains unclear.

为了更好地为院外心脏骤停(OHCA)后的临床决策提供信息,已经开发了许多预测评分,然而,临床医生对使用哪种评分没有达成共识。本综述的目的是确定和比较评分系统,以预测OHCA患者的生存和神经恢复。从建立到2021年12月对MEDLINE数据库进行结构化文献检索。研究开发或验证评分系统,以预测OHCA后的结果。提取相关数据并进行综合整理,进行叙述性综述。总共确定了16个评分系统:一个预测自然循环恢复的概率,六个预测出院生存,九个预测神经系统预后。由于变量的外部验证程度、易用性和高预测价值,NULL-PLEASE和CAST分别被推荐为预测死亡率和神经预后的最佳分数。使用这些评分是否能带来更具成本效益的服务还不清楚。
{"title":"Scoring Systems to Predict Survival or Neurological Recovery after Out-of-hospital Cardiac Arrest.","authors":"Rishi Naik,&nbsp;Indrajeet Mandal,&nbsp;Diana A Gorog","doi":"10.15420/ecr.2022.05","DOIUrl":"https://doi.org/10.15420/ecr.2022.05","url":null,"abstract":"<p><p>Numerous prediction scores have been developed to better inform clinical decision-making following out-of-hospital cardiac arrest (OHCA), however, there is no consensus among clinicians over which score to use. The aim of this review was to identify and compare scoring systems to predict survival and neurological recovery in patients with OHCA. A structured literature search of the MEDLINE database was carried out from inception to December 2021. Studies developing or validating scoring systems to predict outcome following OHCA were selected. Relevant data were extracted and synthesised for narrative review. In total, 16 scoring systems were identified: one predicting the probability of return of spontaneous circulation, six predicting survival to hospital discharge and nine predicting neurological outcome. NULL-PLEASE and CAST are recommended as the best scores to predict mortality and neurological outcome, respectively, due to the extent of external validation, ease of use and high predictive value of the variables. Whether use of these scores can lead to more cost-effective service delivery remains unclear.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/a8/ecr-17-e20.PMC9820201.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Most Recent Trials and Advances in Hypertension. 高血压的最新试验和进展。
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.27
Elías Martínez Rey-Rañal, Alberto Cordero

Hypertension is one of the most prevalent cardiovascular risk factors and blood pressure control remains a clinical challenge, especially for patients with established cardiovascular disease. Late-breaking clinical trials and other evidence in hypertension have evolved to assess the most accurate ways to measure blood pressure, the use of combination therapies, considerations in special populations and evaluation of new techniques. Recent evidence supports the superiority of ambulatory or 24-hour blood pressure measurements, rather than office blood pressure measurements, for the assessment of cardiovascular risk. The use of fixed-dose combinations and polypills has been demonstrated to be valid and to provide clinical benefits beyond blood pressure control. There have also been advances in new approaches such as telemedicine, devices and the use of algorithms. Clinical trials have provided valuable data on blood pressure control in primary prevention, during pregnancy and in the elderly. The role of renal denervation remains unsolved but innovative techniques using ultrasound or alcohol injections are being explored. Current evidence and results of latest trials are summarised in this review.

高血压是最普遍的心血管危险因素之一,控制血压仍然是一项临床挑战,特别是对于已确诊心血管疾病的患者。最新的高血压临床试验和其他证据已经发展到评估最准确的血压测量方法,联合疗法的使用,特殊人群的考虑和新技术的评估。最近的证据支持动态或24小时血压测量优于办公室血压测量,用于评估心血管风险。使用固定剂量的联合用药和多片剂已被证明是有效的,并提供了除控制血压以外的临床益处。在远程医疗、设备和算法的使用等新方法方面也取得了进展。临床试验为初级预防、孕期和老年人血压控制提供了有价值的数据。肾去神经支配的作用仍未得到解决,但正在探索使用超声或酒精注射的创新技术。本综述总结了目前的证据和最新试验的结果。
{"title":"Most Recent Trials and Advances in Hypertension.","authors":"Elías Martínez Rey-Rañal,&nbsp;Alberto Cordero","doi":"10.15420/ecr.2022.27","DOIUrl":"https://doi.org/10.15420/ecr.2022.27","url":null,"abstract":"<p><p>Hypertension is one of the most prevalent cardiovascular risk factors and blood pressure control remains a clinical challenge, especially for patients with established cardiovascular disease. Late-breaking clinical trials and other evidence in hypertension have evolved to assess the most accurate ways to measure blood pressure, the use of combination therapies, considerations in special populations and evaluation of new techniques. Recent evidence supports the superiority of ambulatory or 24-hour blood pressure measurements, rather than office blood pressure measurements, for the assessment of cardiovascular risk. The use of fixed-dose combinations and polypills has been demonstrated to be valid and to provide clinical benefits beyond blood pressure control. There have also been advances in new approaches such as telemedicine, devices and the use of algorithms. Clinical trials have provided valuable data on blood pressure control in primary prevention, during pregnancy and in the elderly. The role of renal denervation remains unsolved but innovative techniques using ultrasound or alcohol injections are being explored. Current evidence and results of latest trials are summarised in this review.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/fe/ecr-17-e24.PMC9947933.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10850771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021 心力衰竭的新试验证据:来自2021年欧洲心脏病学会大会的亮点
IF 3 Q1 Medicine Pub Date : 2022-02-01 DOI: 10.15420/ecr.2022.06
G. Ferrannini, G. Savarese
EMPEROR-Preserved Trial and EMPEROR-Pooled Analysis For the first time, the EMPEROR-Preserved trial proved the efficacy of a pharmacological product in patients with HF with preserved ejection fraction (HFpEF).1 In this study, 5,988 patients with symptomatic HF, ejection fraction (EF) >40% and high levels of natriuretic peptides were randomised to the sodium–glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin (10 mg once daily) or a placebo.
{"title":"New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021","authors":"G. Ferrannini, G. Savarese","doi":"10.15420/ecr.2022.06","DOIUrl":"https://doi.org/10.15420/ecr.2022.06","url":null,"abstract":"EMPEROR-Preserved Trial and EMPEROR-Pooled Analysis For the first time, the EMPEROR-Preserved trial proved the efficacy of a pharmacological product in patients with HF with preserved ejection fraction (HFpEF).1 In this study, 5,988 patients with symptomatic HF, ejection fraction (EF) >40% and high levels of natriuretic peptides were randomised to the sodium–glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin (10 mg once daily) or a placebo.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76068042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1